Adaptive Biotechnologies Corporation (ADPT)

Market Cap	1.84B
Revenue (ttm)	189.53M
Net Income (ttm)	-141.84M
Shares Out	151.92M
EPS (ttm)	-0.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,654,417
Open	11.97
Previous Close	11.93
Day's Range	11.84 - 12.36
52-Week Range	3.47 - 12.43
Beta	1.83
Analysts	Strong Buy
Price Target	10.57 (-12.5%)
Earnings Date	Jul 31, 2025

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as M...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 27, 2019
• Employees: 619
• Stock Exchange: NASDAQ
• Ticker Symbol: ADPT
• Website: https://www.adaptivebiotech.com

Financial Performance

In 2024, Adaptive Biotechnologies's revenue was $178.96 million, an increase of 5.10% compared to the previous year's $170.28 million. Losses were -$159.49 million, -29.19% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for ADPT stock is "Strong Buy." The 12-month stock price target is $10.57, which is a decrease of -12.50% from the latest price.

Price Target

$10.57

(-12.50% downside)

Analyst Consensus: Strong Buy